tradingkey.logo
tradingkey.logo
Search

Precigen Inc

PGEN
Add to Watchlist
5.250USD
-0.450-7.89%
Close 07/01, 16:00ETQuotes delayed by 15 min
1.87BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表
Intraday
1m
30m
1h
D
W
M
D

Today

-7.89%

5 Days

-2.78%

1 Month

+27.43%

6 Months

+25.60%

Year to Date

+25.60%

1 Year

+262.07%

Key Figures
5.650Open
5.665High
7.61MVolume
LossP/E TTM
24.87P/E Dynamic
--Dividend TTM
2.14%Turnover Ratio
5.700Prev. Close
5.200Low
29.54MTurnover
LossP/E Static
92.34P/B
0.00%Div Yield TTM
-152.89%ROA
5.46552wk High
1.16Volume Ratio
-126.23MNet Profit
355.90MShares
-1.2108EPS TTM
1.07Beta
-12418.40%ROE
1.28052wk Low
8.16%Amplitude
88.99%Gross Margin
1.87BMarket Cap
9.38Reward/Risk
5.08%Risk Rate

TradingKey Stock Score of Precigen Inc

Currency: USD Updated: 2026-07-01

Key Insights

Precigen Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 54 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.50.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Precigen Inc's Score

Industry at a Glance

Industry Ranking
54 / 157
Overall Ranking
140 / 4564
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Precigen Inc Highlights

StrengthsRisks
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 55.57% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.68M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 9.68M.
Undervalued
The company’s latest PE is -4.34, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 270.08M shares, increasing 5.66% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 5.84M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.43.

Analyst Rating

Based on 3 analysts
Buy
Current Rating
12.500
Target Price
+119.30%
Upside Space

Precigen Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Precigen Inc Info

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Ticker SymbolPGEN
CompanyPrecigen Inc
CEOSabzevari (Helen)
Websitehttps://precigen.com/

FAQs

What is the current price of Precigen Inc (PGEN)?

The current price of Precigen Inc (PGEN) is 5.25.

What is the symbol of Precigen Inc?

The ticker symbol of Precigen Inc is PGEN.

What is the 52-week high of Precigen Inc?

The 52-week high of Precigen Inc is 5.46.

What is the 52-week low of Precigen Inc?

The 52-week low of Precigen Inc is 1.28.

What is the market capitalization of Precigen Inc?

The market capitalization of Precigen Inc is 1.87B.

Is Precigen Inc (PGEN) currently rated as Buy, Hold, or Sell?

According to analysts, Precigen Inc (PGEN) has an overall rating of Buy, with a price target of 12.50.

What is the Earnings Per Share (EPS TTM) of Precigen Inc (PGEN)?

The Earnings Per Share (EPS TTM) of Precigen Inc (PGEN) is -1.37.